Similar articles

• O-(beta-hydroxyethyl)-rutosides (Paroven; Venoruton): new studies, improved safety, and novel cardiovascular applications.

  Cesarone MR, Belcaro G, Grossi MG. Cesarone MR, et al. Angiology. 2008 Feb-Mar;59 Suppl 1:5S-6S. doi: 10.1177/0003319707313094. Angiology. 2008. PMID: 18287161 No abstract available.
• [New aspects in the pathogenesis of chronic venous insufficiency and the place of localized action of Venoruton].

  Bekers S, Zilstra I. Bekers S, et al. Akush Ginekol (Sofiia). 2002;41 Suppl 2:28-32. Akush Ginekol (Sofiia). 2002. PMID: 19705689 Bulgarian. No abstract available.
• Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency.

  Rehn D, Golden G, Nocker W, Diebschlag W, Lehmacher W. Rehn D, et al. Arzneimittelforschung. 1993 Oct;43(10):1060-3. Arzneimittelforschung. 1993. PMID: 8267669 Clinical Trial.
• Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions.

  Perrin M, Ramelet AA. Perrin M, et al. Eur J Vasc Endovasc Surg. 2011 Jan;41(1):117-25. doi: 10.1016/j.ejvs.2010.09.025. Epub 2010 Dec 3. Eur J Vasc Endovasc Surg. 2011. PMID: 21126890 Review.
• Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon.

  Frick RW. Frick RW. Angiology. 2000 Mar;51(3):197-205. doi: 10.1177/000331970005100303. Angiology. 2000. PMID: 10744007 Review.